Advertisement

Internal and Emergency Medicine

, Volume 12, Issue 5, pp 561–563 | Cite as

Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes

  • Davide Imberti
  • Daniela MastroiacovoEmail author
DEBATE

Abstract

In the Hokusai-VTE trial, 733 patients were treated with the reduced dose edoxaban regimen, which maintained efficacy and safety compared with the 60 mg dose, and was safer than warfarin. The prophylactic doses of apixaban and rivaroxaban reduced the risk of recurrent venous thromboembolism (VTE) in the extended treatment trials. Dabigatran 110 mg was approved by the European Medicine Agency for VTE treatment. Further data from registries and real-world studies will help to clarify whether patients, with other specific characteristics, can benefit from the reduced dose of direct oral anticoagulants.

Keywords

Venous thromboembolism Direct oral anticoagulants (DOACs) Lower dose 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal informed consent is not required.

References

  1. 1.
    Van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:320–328CrossRefPubMedGoogle Scholar
  2. 2.
    Dentali F, Di Minno MN, Gianni M, Ambrosino P, Squizzato A, Ageno W (2015) Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature. Intern Emerg Med 10(4):507–514CrossRefPubMedGoogle Scholar
  3. 3.
    Imberti D, Pomero F, Benedetti R, Fenoglio L (2016) Safety and efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Intern Emerg Med 11(7):895–900CrossRefPubMedGoogle Scholar
  4. 4.
    Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J (2016) Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41(1):206–232CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Madan S, Shah S, Dale P, Partovi S, Parikh SA (2016) Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther 6(6):570–581CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415CrossRefGoogle Scholar
  7. 7.
    Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ (2016) Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med 129(11):1198–1204CrossRefPubMedGoogle Scholar
  8. 8.
    Trujillo-Santos J, Di Micco P, Dentali F, Douketis J, Díaz-Peromingo JA, Núñez MJ, Cañas I, Mastroiacovo D, Saraiva de Sousa M, Monreal M, Investigators RIETE (2017) Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 117(2):382–389CrossRefPubMedGoogle Scholar
  9. 9.
    Van ESN, Büller HR (2015) Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations. Hematol Am Soc Hematol Educ Program 2015:125–131Google Scholar
  10. 10.
    Bertoletti L, Ollier E, Duvillard C, Delavenne X, Beyens MN, De Magalhaes E, Bellet F, Basset T, Mismetti P, Laporte S (2017) Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res 118:33–42CrossRefPubMedGoogle Scholar
  11. 11.
    Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H (2016) Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost 116(4):747–753CrossRefPubMedGoogle Scholar
  12. 12.
    Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, Investigators AMPLIFY-EXT (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368(8):699–708CrossRefPubMedGoogle Scholar
  13. 13.
    Weitz JI, Lensing AW, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MC, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, EINSTEIN CHOICE Investigators (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 376(13):1211–1222CrossRefPubMedGoogle Scholar
  14. 14.
    Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, Investigators PREVENT (2003) Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 348(15):1425–1434CrossRefPubMedGoogle Scholar
  15. 15.
    Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M (2013) Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631–639CrossRefGoogle Scholar
  16. 16.
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146–153CrossRefPubMedGoogle Scholar
  17. 17.
    European Medicine Agency (2014) Pradaxa: EPAR-product information. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000829/WC500041059.pdf. Accessed 20 March 2017
  18. 18.
    Prisco D, Ageno W, Becattini C, D’Angelo A, Davì G, De Cristofaro R, Dentali F, Di Minno G, Falanga A, Gussoni G, Masotti L, Palareti G, Pignatelli P, Santi RM, Santilli F, Silingardi M, Tufano A, Violi F, SIMI (Italian Society of Internal Medicine), FADOI (Federation of Associations of Hospital Doctors on Internal Medicine), SISET (Italian Society for the Study of Haemostasis and Thrombosis) (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 12(3):387–406CrossRefPubMedGoogle Scholar
  19. 19.
    Van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968–1975CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2017

Authors and Affiliations

  1. 1.Internal Medicine Department, Piacenza HospitalHaemostasis and Thrombosis CenterPiacenzaItaly
  2. 2.Angiology UnitSS Filippo and Nicola HospitalAvezzanoItaly

Personalised recommendations